Article
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Blood - 6 Mar 2014
Rumi Elisa, Pietra Daniela, Ferretti Virginia, Klampfl Thorsten, Harutyunyan Ashot S, Milosevic Jelena D, Them Nicole C C, Berg Tiina, Elena Chiara, Casetti Ilaria C, Milanesi Chiara, Sant'antonio Emanuela, Bellini Marta, Fugazza Elena, Renna Maria C, Boveri Emanuela, Astori Cesare, Pascutto Cristiana, Kralovics Robert, Cazzola Mario
Abstract excerpt
Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential thrombocythemia according to JAK2 or CALR mutation status and in relation to those of polycythemia vera. The mutant allele burden was lower in JAK2-mutated than in CALR-mutated essential thrombocythemia. Patients with JAK2 (V617F) were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.